Siogen links with Veeda to add value to doxorubicin
This article was originally published in Scrip
Executive Summary
Siogen Biotech, a Malaysian/European venture, has entered into an alliance with the Indian contract research organisation Veeda Clinical Research for the clinical development of a novel formulation of doxorubicin.